PetMed Express (PETS) Expected to Announce Quarterly Earnings on Monday

PetMed Express (NASDAQ:PETS) is projected to issue its Q4 2026 resultson Monday, May 11th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $52.00 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Monday, June 8, 2026 at 4:00 PM ET.

PetMed Express (NASDAQ:PETS) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.44). The firm had revenue of $40.66 million during the quarter, compared to the consensus estimate of $54.04 million. PetMed Express had a negative net margin of 35.51% and a negative return on equity of 70.81%. On average, analysts expect PetMed Express to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

PetMed Express Trading Down 1.1%

Shares of PETS traded down $0.03 during mid-day trading on Monday, reaching $2.28. 26,309 shares of the stock traded hands, compared to its average volume of 129,662. The company has a market cap of $48.69 million, a price-to-earnings ratio of -0.73 and a beta of 0.78. PetMed Express has a 1 year low of $1.57 and a 1 year high of $4.32. The firm has a fifty day moving average price of $2.44 and a 200 day moving average price of $2.66.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded PetMed Express to a “hold” rating in a research report on Thursday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, PetMed Express presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PETS. Empowered Funds LLC boosted its position in PetMed Express by 14.2% in the fourth quarter. Empowered Funds LLC now owns 68,651 shares of the company’s stock worth $220,000 after purchasing an additional 8,535 shares during the last quarter. Man Group plc raised its position in PetMed Express by 10.7% in the fourth quarter. Man Group plc now owns 167,152 shares of the company’s stock worth $535,000 after acquiring an additional 16,113 shares during the period. Bridgeway Capital Management LLC boosted its stake in shares of PetMed Express by 17.2% during the 4th quarter. Bridgeway Capital Management LLC now owns 126,351 shares of the company’s stock worth $404,000 after acquiring an additional 18,535 shares during the last quarter. Jain Global LLC bought a new stake in shares of PetMed Express during the 4th quarter valued at $78,000. Finally, Steel Partners Holdings L.P. purchased a new stake in shares of PetMed Express in the 4th quarter worth $620,000. Institutional investors own 73.33% of the company’s stock.

PetMed Express Company Profile

PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.